



May 7, 2025

Company Name: Japan Lifeline Co., Ltd.
 Representative: Keisuke Suzuki, President and CEO
 (Security Code: 7575; TSE Prime Market)
 Inquiries: Takeyoshi Egawa, Chief Financial Officer,
 Head of Corporate Management Group
 (TEL. +81-3-6711-5200)

Japan Lifeline Revises Upward Medium-Term Targets

TOKYO, JAPAN – May 7, 2025 – Japan Lifeline Co., Ltd. (“the Company”) is pleased to announce that at the Board of Directors meeting held today, the Company resolved to upwardly revise the financial targets for the fiscal year ending March 2028, the final year of the Medium-Term Management Plan (FYE2024-FYE2028) originally announced on May 10, 2023.

Besides the current key initiatives, the Company has established four new growth strategies: "Entry into the Structural Heart Therapeutic Area," "Co-development of PFA Products and Entry into the Global PFA Market," "Expansion of Global Sales," and "Advancing OEM Manufacturing." The Company aims to achieve these revised financial targets through these strategic initiatives.

1. Revision of Targets

Numerical Targets of the Medium-Term Management Plan (FYE March 2024-FYE March 2028)

Quantitative Target	Fiscal year ending March 31, 2028 Previous target	Fiscal year ending March 31, 2028 New target	Revision details
Net sales	63.0 billion yen	70.0 billion yen	+7.0 billion yen
Net sales from new business areas	8.0 billion yen	11.0 billion yen	+3.0 billion yen
Operating margin	Standard of 20% each year	Standard of 20% each year	No change
ROIC	12%	13%	+100 bps
EPS	120 yen	145 yen	+25 yen

2. Reason for Revision

The Medium-Term Management Plan covering FYE2024 to FYE2028 established five financial targets, supported by three key initiatives: "Expanding New Therapeutic Areas," "Continuous Introduction of Competitive Products," and "Strengthening Capital-Efficient Management."

After completing the second year (FYE2025) and reviewing both progress and medium-term outlook, the Company projects exceeding the initial FYE2028 financial targets. This assessment prompted the upward revision of targets as indicated above.

Performance through FYE2025 demonstrates steady progress. In "Expanding New Therapeutic Areas," Neurovascular and Gastrointestinal products have penetrated markets successfully. The "Continuous

Introduction of Competitive Products" initiative strengthened the lineup of high-profit proprietary products including intracardiac defibrillation catheters and Frozen Elephant Trunk products, minimizing competitive impacts. The recently launched hemostasis device for femoral vein grew into a 2 billion yen business within one year. "Strengthening Capital-Efficient Management" initiatives delivered enhanced shareholder returns through share repurchases, achieving earnings per share of 131.43 yen in FYE2025, representing a 33% year-over-year increase.

The medium-term outlook remains positive. Procedural volume growth exceeds initial projections, creating favorable conditions for the core EP/Ablation business. The Company now forecasts atrial fibrillation procedure growth at approximately 9% five-year CAGR, up from the initial 6% projection.

Additionally, the Company will vigorously pursue four new growth strategies besides existing initiatives:

New Growth Strategies	Strategic Category
1) Entry into the Structural Heart Therapeutic Area	"Expanding New Therapeutic Areas"
2) Co-development of PFA Products and Entry into the Global PFA Market	"Continuous Introduction of Competitive Products"
3) Expansion of Global Sales	Additional Key Priorities
4) Advancing OEM Manufacturing	Additional Key Priorities

The Structural Heart Therapeutic strategy begins with transcatheter aortic valve implantation/replacement (TAVI/TAVR) and will expand to build a comprehensive portfolio in this high-growth area. While generating revenue from procured products, this segment promises high profit margins and will likely emerge as a significant performance driver in the medium-to-long term.

The PFA Products strategy involves collaboration with U.S.-based CardioFocus to develop new Pulsed Field Ablation products, widely recognized as a game-changer in the EP/Ablation space. This partnership combines the Company's expertise in highly maneuverable catheter manufacturing with CardioFocus's clinical and device knowledge, targeting the global PFA market estimated at potentially 1 trillion yen.

The Global Sales strategy accelerates development of overseas distribution channels for the Company's proprietary EP/Ablation, Cardiovascular, and Gastrointestinal products. By FYE2028, distribution will expand to over ten countries, primarily in the Middle East and Asia where Japanese regulatory approvals provide advantages, while simultaneously advancing quality management systems for U.S. FDA and European CE approvals. Long-term goals include exporting core proprietary products to the U.S. and European markets.

The OEM Manufacturing strategy leverages the Company's catheter manufacturing expertise to create new business opportunities.

Based on these considerations, the Company has decided to raise the financial targets for FYE2028, the final year of the Medium-Term Management Plan. For further details, please refer to the "Full-Year FYE3/2025 Results", which is an IR slide deck (P26-P48) disclosed on the same day, available at www.japanlifeline.com/investors/